The medical sector continues to rise, the sector rises nearly 5%, and the valuation is still lower than the time interval of 99%of history

On the afternoon of the 4th, the medical sector continued to rise and stronger, Nuo He's source rose 17%, Midicean rose more than 10%, Zhaoyan's new drugs rose daily limit, and the concepts of CXOs such as Kailei, Tiger Pharmaceutical, and Kang Longcheng rose more than 7%, CSI Medical Index rose nearly 5%.

As of the release of 13:37, the largest medical ETF (512170) of the two cities rose more than 4.3%, the transaction was nearly 500 million yuan, and the price returned to the 0.6 yuan integer mark.Last week's medical ETF (512170) net purchase funds of more than 380 million yuan, and the fund share rose to 25.3 billion yuan, a new high listing high.

Guojin Securities said that domestic epidemic prevention and control is strong, routine medical treatment is rapid, and the medical sector is expected to usher in both performance and valuation.Policy expectations such as collecting and mining in 2022 have been relatively sufficient, and the overall valuation of the medical device sector is outstanding, and the future performance and valuation are expected to usher in dual repair.The consumer medical sector online and offline consumer demand has continued to recover, and its performance is optimistic.

The latest data shows that the latest valuation of the CSI Medical Index is 30.64 times, which is still lower than the data interval of more than 99%of history.

- END -